BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19925830)

  • 1. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.
    McColl DJ; Chen X
    Antiviral Res; 2010 Jan; 85(1):101-18. PubMed ID: 19925830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
    de Béthune MP
    Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
    Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
    Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrase inhibitors in the treatment of HIV-1 infection.
    Powderly WG
    J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management of HIV-1 resistance.
    Paredes R; Clotet B
    Antiviral Res; 2010 Jan; 85(1):245-65. PubMed ID: 19808056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 integrase inhibitors: 2005-2006 update.
    Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N
    Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic strategies for raltegravir.
    Garrido C; Soriano V; de Mendoza C
    J Antimicrob Chemother; 2010 Feb; 65(2):218-23. PubMed ID: 20016017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
    Mazumder A; Wang S; Neamati N; Nicklaus M; Sunder S; Chen J; Milne GW; Rice WG; Burke TR; Pommier Y
    J Med Chem; 1996 Jun; 39(13):2472-81. PubMed ID: 8691444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):419-26. PubMed ID: 18662108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyrtiosal, from the marine sponge Hyrtios erectus, inhibits HIV-1 integrase binding to viral DNA by a new inhibitor binding site.
    Du L; Shen L; Yu Z; Chen J; Guo Y; Tang Y; Shen X; Jiang H
    ChemMedChem; 2008 Jan; 3(1):173-80. PubMed ID: 17943714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer.
    Voet AR; Maeyer MD; Debyser Z; Christ F
    Future Med Chem; 2009 Oct; 1(7):1259-74. PubMed ID: 21426102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Running a tightrope: regulatory challenges in the development of antiretrovirals.
    Naeger LK; Struble KA; Murray JS; Birnkrant DB
    Antiviral Res; 2010 Jan; 85(1):232-40. PubMed ID: 19665489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.